Genetic polymorphisms associated with 5-fluorouracil-induced neurotoxicity

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 313-317

  Kim, Suk Ran ^a   Park, Chang Hun ^a   Park, Silvia ^a   Park, Joon Oh ^a   Lee, Jeeyun ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

5 Fluorouracil; DPYD; Genetic polymorphism; Hyperammonemia; MTHFR; Neurotoxicity; Pharmacogenetics; TYMS

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLORIDE; CREATININE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; LACTIC ACID; LACTULOSE; OXALIPLATIN; POTASSIUM; SODIUM; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ADULT; ALKALOSIS; AMMONIA BLOOD LEVEL; ARTERIAL GAS; ARTICLE; BLOOD GAS ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CONTINUOUS INFUSION; DROWSINESS; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAPHY; ENHANCER REGION; FEMALE; GASTRECTOMY; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDRATION; HYPERAMMONEMIA; HYPOCAPNIA; MALE; METASTASIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; STUPOR; TUMOR SUPPRESSOR GENE; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; SEQUENCE DELETION; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 77955523615     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320032     Document Type: Article

References (33)

1. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
2. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′ -terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-197.
3. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
4. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-2904.
5. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ: Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther 2009, Epub ahead of print.
6. Allegra CJ: Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil? Clin Cancer Res 1999; 5: 1947-1949.
7. Milano G, McLeod HL: Can dihydropyrimidine dehydrogenase impact 5-fluorouracilbased treatment? Eur J Cancer 2000; 36: 37-42.
8. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M: Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil- related side effects. Hum Mutat 2003; 22: 498.
9. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F, Meindl A: Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine- related toxicity in cancer patients. PLoS One 2008; 3:e4003.
10. Yasumatsu R, Nakashima T, Uryu H, Ayada T, Wakasaki T, Kogo R, Masuda M, Fukushima M, Komune S: Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 2009; 55: 36-41.
11. De Mattia E, Toffoli G: C677t and a1298c MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333-1351.
12. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 2008; 26: 2131-2138.
13. Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M: Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer: a singleinstitution outcome study. Chemotherapy 2008; 54: 395-403.
14. Liaw CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, Lin YC, Liaw SJ, Yeh CT: Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999; 10: 275-281.
15. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253.
16. Shehata N, Pater A, Tang SC: Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Cancer Invest 1999; 17: 201-205.
17. Yeh KH, Cheng AL: High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 1997; 75: 464-465.
18. Koenig H, Patel A: Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 1970; 23: 155-160.
19. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC: Intermediate dose 5-fluorouracil- induced encephalopathy. Jpn J Clin Oncol 2006; 36: 55-59.
20. Kim SR, Ozawa S, Saito Y, Kurose K, Kaniwa N, Kamatani N, Hamaguchi T, Shirao K, Muto M, Ohtsu A, Yoshida T, Matsumura Y, Saijo N, Sawada J: Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS). Drug Metab Pharmacokinet 2006; 21: 509-516.
21. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
22. Formica V, Leary A, Cunningham D, Chua YJ: 5-fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 2006; 58: 276-278.
23. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY: Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007; 29: 190-196.
24. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-223.
25. Zintzaras E, Ziogas DC, Kitsios GD, Papathanasiou AA, Lau J, Raman G: MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics 2009; 10: 1285-1294.
26. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827-830.
27. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-386.
28. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-1786.
29. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14: 319-327.
30. Pirzada NA, Ali II, Dafer RM: Fluorouracilinduced neurotoxicity. Ann Pharmacother 2000; 34: 35-38.
31. Ki SS, Jeong JM, Kim SH, Jeong SH, Lee JH, Han CJ, Kim YC, Lee JO, Hong YJ: A case of neurotoxicity following 5-fluorouracilbased chemotherapy. Korean J Intern Med 2002; 17: 73-77.
32. Teraishi F, Suzuki T, Nakamoto M, Chikuba A, Nezu M, Shimamura H, Watanabe T, Matsuda T, Takiue T, Chikuba H: A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6. Gan To Kagaku Ryoho 2009; 36: 867-869.
33. Lazar A, Mau-Holzmann UA, Kolb H, Reichenmiller HE, Riess O, Schomig E: Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004; 27: 559-562.